Active Ingredient(s): Neratinib Maleate
FDA Approved: * July 17, 2017
Pharm Company: * PUMA BIOTECH
Category: Cancer

Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.[2][3] The most common side effect is diarrhea, which affects nearly all patients.[3] Other common side effects include nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.[3] Contents 1 Medical uses 2 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Nerlynx 48.31 mg Oral Tablet
NDC: 70437-240
Puma Biotechnology, Inc.